Integrated Proteins re-designates Hiren Shah as CMD for five-year term
Integrated Proteins has approved the re-designation of Hiren Dhirajlal Shah from Additional Executive Director to Chairman and Managing Director for a five-year term starting July 24, 2026. The move aims to consolidate leadership and requires shareholder ratification at an upcoming Extra-Ordinary General Meeting.

*this image is generated using AI for illustrative purposes only.
Integrated Proteins has consolidated its leadership structure by approving the re-designation of Hiren Dhirajlal Shah as Chairman and Managing Director (CMD). The Board of Directors sanctioned the change during a meeting held on July 24, 2026, at the company’s registered office in Jamnagar, Gujarat. This strategic shift elevates Shah from his previous role as Additional Executive Director, signaling a focused approach to corporate governance and executive oversight for the listed protein products manufacturer. The appointment is subject to ratification by shareholders at an Extra-Ordinary General Meeting (EGM).
The Board scheduled the EGM for August 20, 2026, to be conducted via Video Conferencing or Other Audio Visual Means (OAVM). Shareholders holding shares as of the cut-off date of August 13, 2026, will be eligible to vote. The e-voting window opens on August 17, 2026, at 9:00 AM and closes on August 19, 2026, at 5:00 PM. Mrs. Ankita Tejas Shah, a Practicing Company Secretary (Membership No: A43289), has been appointed as the scrutinizer for the e-voting process.
Shah’s tenure as CMD will span five years, commencing on July 24, 2026, and concluding on July 23, 2031. The Board’s decision aligns with Sections 196, 197, and 203 of the Companies Act, 2013, read with Schedule V, and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The filing confirms that Shah is not debarred from holding directorial office by the Securities and Exchange Board of India (SEBI) or any other regulatory authority.
The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026. The company filed the details with BSE Limited, where it is listed under Scrip Code 519606.
Key Details of the Appointment
| Particulars | Details |
|---|---|
| Appointee | Hiren Dhirajlal Shah |
| New Designation | Chairman and Managing Director |
| Previous Role | Additional Executive Director |
| DIN | 09842161 |
| Tenure Start Date | July 24, 2026 |
| Tenure End Date | July 23, 2031 |
| Shareholder Approval | Required at EGM |
Leadership Profile
Hiren Dhirajlal Shah brings a multidisciplinary background to the top leadership role. He holds a Bachelor of Computer Applications (BCA) and a Bachelor of Laws (LL.B.) degree from Saurashtra University. His professional expertise spans finance, accounting, business administration, and corporate management. Over the years, Shah has been actively involved in financial planning, regulatory compliance, and strategic decision-making, providing Integrated Proteins with experienced oversight in both operational and legal domains. The Board noted no relationship disclosures between directors regarding this appointment.
Historical Stock Returns for Integrated Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.39% | -2.35% | -4.29% | +356.45% | +217.62% | +4,321.87% |
How might Hiren Dhirajlal Shah's dual background in law and computer applications influence Integrated Proteins' digital transformation and regulatory compliance strategies over his five-year tenure?
What specific operational or strategic initiatives is the Board prioritizing by consolidating leadership under a single Chairman and Managing Director rather than maintaining a distributed executive structure?
Given the upcoming EGM on August 20, 2026, are there any indications of dissent among institutional investors regarding this leadership consolidation?


































